前列腺上皮基因定义治疗相关的前列腺癌分子亚型
研究基于公共RNA测序数据定义1629个前列腺上皮细胞表达基因,通过共识聚类在TCGA训练集中识别出四种前列腺腺癌亚型:luminal A、luminal S、AVPC-I和AVPC-M。AVPC-I和AVPC-M预测对雄激素受体信号抑制剂耐药且每肿瘤负荷PSA低;luminal A和AVPC-M预测对多西他赛耐药且PSA/PAP比值高。转移性前列腺癌患者高PSA/PAP比值(>20)接受多西他赛化疗后无进展生存期显著短于低比值(≤20)者。
要点
- 基于上皮基因表达可划分四种前列腺癌亚型,具有不同转录组、基因组和病理特征。
- AVPC-I和AVPC-M亚型预测对雄激素受体信号抑制剂耐药且每肿瘤负荷PSA低。
- 高PSA/PAP比值(>20)的转移性患者多西他赛化疗后无进展生存期更短。
核心结论
- 提出四种具有不同转录组、基因组和病理特征的前列腺腺癌亚型。
- 晚期癌症中PSA/PAP比值可能有助于确定哪些患者可从最大化雄激素受体抑制或早期使用抗微管药物中获益。
研究设计与样本
- 通过分析公共批量和单细胞RNA测序数据定义1629个前列腺上皮细胞表达基因。
- 使用共识聚类和CIBERSORT去卷积进行类别发现和比例估计分析。
- 以癌症基因组图谱前列腺腺癌数据集作为训练集。
- 分析血清标志物PSA和PAP以预测转移情况下多西他赛化疗反应。
主要发现
- 识别出两种管腔亚型和两种侵袭性变异亚型:管腔A(脂肪生成/AR活跃/PSA高)占30.0%,管腔S(分泌型/PAP高)占26.0%,AVPC-I(免疫浸润型)占14.7%,AVPC-M(Myc活跃型)占4.2%,混合型占25.0%。
- AVPC-I和AVPC-M亚型预测对ARI耐药且每肿瘤负荷PSA低。
- 管腔A和AVPC-M预测对多西他赛耐药且PSA/PAP比值高。
- 转移性前列腺癌患者中PSA/PAP比值高(>20)者接受多西他赛化疗后无进展生存期显著短于低比值(≤20)者。
临床怎么用
- PSA/PAP比值在晚期癌症中可能辅助判断患者从最大化雄激素受体抑制或早期抗微管药物治疗中的获益。
局限性
- 无监督聚类分析受潜在混杂因素如基质污染和应激相关物质降解的阻碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Transcriptomic landscape of prostate cancer (PCa) shows multidimensional variability, potentially arising from the cell-of-origin, reflected in serum markers, and most importantly related to drug sensitivities. For example, Aggressive Variant Prostate Cancer (AVPC) presents low PSA per tumor burden, and characterized by de novo resistance to androgen receptor signaling inhibitors (ARIs). Understanding PCa transcriptomic complexity can provide biological insight and therapeutic guidance. However, unsupervised clustering analysis is hindered by potential confounding factors such as stromal contamination and stress-related material degradation. MATERIALS AND METHODS: To focus on prostate epithelial cell-relevant heterogeneity, we defined 1,629 genes expressed by prostate epithelial cells by analyzing publicly available bulk and single- cell RNA sequencing data. Consensus clustering and CIBERSORT deconvolution were used for class discovery and proportion estimate analysis. The Cancer Genome Atlas Prostate Adenocarcinoma dataset served as a training set. The resulting clusters were analyzed in association with clinical, pathologic, and genomic characteristics and impact on survival. Serum markers PSA and PAP was analyzed to predict response to docetaxel chemotherapy in metastatic setting. RESULTS: We identified two luminal subtypes and two aggressive variant subtypes of PCa: luminal A (Adipogenic/AR-active/PSA-high) (30.0%); luminal S (Secretory/PAP-high) (26.0%); AVPC-I (Immune-infiltrative) (14.7%), AVPC-M (Myc-active) (4.2%), and mixed (25.0%). AVPC-I and AVPC-M subtypes predicted to be resistant to ARI and have low PSA per tumor burden. Luminal A and AVPC-M predicted to be resistant to docetaxel and have high PSA/PAP Ratio. Metastatic PCa patients with high PSA/PAP ratio (>20) had significantly shorter progression-free survival than those with low ratio (≤20) following docetaxel chemotherapy. CONCLUSION: We propose four prostate adenocarcinoma subtypes with distinct transcriptomic, genomic, and pathologic characteristics. PSA/PAP ratio in advanced cancer may aid in determining which patients would benefit from maximized androgen receptor inhibition or early use of antimicrotubule agents.
引用
- Han H, Lee HH, Choi K, et al. Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype. Prostate Cancer Prostatic Dis. 2021. PMID: 33903734. doi:10.1038/s41391-021-00364-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。